已发表论文

NEDD9 过度表达预示实体癌的预后不良:荟萃分析

 

Authors Gu Y, Lu J, Chen C, Zheng F

Received 17 February 2019

Accepted for publication 26 April 2019

Published 28 May 2019 Volume 2019:12 Pages 4213—4222

DOI https://doi.org/10.2147/OTT.S205760

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Ms Rachel Predeepa

Peer reviewer comments 3

Editor who approved publication: Dr XuYu Yang

Background: The oncogenicity of neural precursor cell-expressed developmentally down-regulated 9 (NEDD9) has been demonstrated in multiple cancer types. However, the prognostic value of NEDD9 in some solid cancers remains controversial. Thus, this meta-analysis was conducted to evaluate the relationship between NEDD9 expression survival rates in solid tumors.
Method: Our meta-analysis included studies searched from various search engines with specific inclusion criteria and exclusion criteria. Combined HRs for overall survival (OS) and disease-free survival (DFS) or progression-free survival (PFS) or recurrence-free survival (RFS) or cancer-specific survival (CSS) were assessed using fixed-effects and random-effects models. The source of heterogeneity was identified by subgroup analysis. Additionally, publication bias was assessed using funnel plot and Egger’s regression asymmetry test.
Result: Eighteen studies with a total of 2,476 patients were retrieved for analysis. Pooled HRs and 95% CIs were calculated. Both OS (HR=1.82; 95% CI: 1.43–2.31) and DFS/PFS/RFS/CSS (HR=2.54; 95% CI: 1.93–3.33) indicated that NEDD9 overexpression is associated with poor OS in cancer patients with solid tumors.
Conclusion: NEDD9 overexpression might be a potential marker to predict prognosis in solid cancer patients.
Keywords: NEDD9, solid cancer, prognosis, meta-analysis




Figure 1 Flow diagram of the study selection process.